title: A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer. EORTC Lung Cancer Working Party.
abstract: We conducted a randomized trial testing etoposide (120 mg/m2 d1-3) + vindesine (3 mg/m2 d1) with or without cisplatin (60 mg/m2 d1) in patients with SCLC. A total of 8 courses were given at 3-week intervals. 221 patients were registered and 201, 95 in the CEV arm and 106 in the EV arm, were eligible for survival analysis. 183 patients were evaluable for response: 74% had an objective response (OR) with CEV versus 55% with EV (p = 0.01). Complete response rates were, respectively, 21% and 13% (NS). In patients with limited disease (LD), OR rates were 72% and 61% (NS), and 76% and 48% in extensive disease (ED) (p = 0.01). There was no statistically significant difference in survival between the two regimens (p = 0.745, log rank test). Median survival for EV and CEV were, respectively, 40 and 45 weeks, and two-year survivals were 11% and 9%; in patients with LD, the corresponding figures were 14% and 16% (NS) and in those with ED, 8% and 3% (NS). Disease extent (LD vs ED), Karnofsky performance status and loss of body weight were significant prognostic factors for survival; age, sex, type of treatment and type of lesion were not. The CEV regimen was not significantly more myelotoxic than EV but was associated with more severe nausea, vomiting and alopecia. In conclusion, the addition of cisplatin to the EV regimen, a combination reported to be easily manageable, was associated with a significantly higher OR rate but survival was not significantly improved.
authors.affiliation: Institut Jules Borden, Brussels, Belgium.
authors.forename: J P
authors.initials: JP
authors.lastname: Sculier
authors.forename: J
authors.initials: J
authors.lastname: Klastersky
authors.forename: P
authors.initials: P
authors.lastname: Libert
authors.forename: P
authors.initials: P
authors.lastname: Ravez
authors.forename: J
authors.initials: J
authors.lastname: Thiriaux
authors.forename: J
authors.initials: J
authors.lastname: Lecomte
authors.forename: G
authors.initials: G
authors.lastname: Bureau
authors.forename: G
authors.initials: G
authors.lastname: Vandermoten
authors.forename: G
authors.initials: G
authors.lastname: Dabouis
authors.forename: J
authors.initials: J
authors.lastname: Michel
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D014751:Vindesine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D005047:Etoposide; D002945:Cisplatin; D014751:Vindesine